Advanced Therapy Medicinal Products Market Growth Drivers and Challenges:
Growth Drivers
- Rising Problems of Genetic Diseases - An illness characterized by one or more anomalies in the genome is referred to as a genetic condition. Advanced therapy medicinal products are one of the most effective ways to treat genetic disorder. According to the World Health Organization, around 2%–5% of all live births are affected by genetic illnesses and congenital anomalies, which can also be responsible for up to 50% of infant fatalities and 30% of pediatric hospital admissions in developed nations.
- Increase in Neurological Disorders - Neurological disorder has become more prevalent among the people. People are getting affected by dementia, Alzheimer’s disease and others. As per the statistics of the United Nations, every year around 6.8 million people die of maladies, moreover, every 1 in 6th person is suffering from a neurological disorder.
- Higher Demand for Gene Therapy - Gene therapy is used to replace the faulty gene and add the fit gene to the body. this procedure helps in fighting various diseases, such as cancer, AIDS, diabetes, and others. The number of people to be treated by gene therapy is estimated to be around 1 million from the year 2020 to 2035.
- Growing Investment in Advanced Therapy Medicinal Products - With the increase in investment in the market, the research and development of advanced therapy medicinal products are also rising. In 202o, around USD 360 million were invested in cell therapy alone, and by 2021 it grew to nearly USD 70 billion.
- Rise in the Development of New and Better Solutions - By the reports of the World Economic Forum, currently, there are more than 2000 advanced therapies in the development stage, and they are expected to treat larger pool of diseases.
Challenges
- Advanced therapy medicinal products are not cost-effective- Advanced therapy medicinal products are typically highly customized or catered to a certain group of patients. As a result, it is challenging to automate or conform to good manufacturing standards in their manufacturing to achieve commercialization at an affordable level. Therefore, the high cost of the products is to hamper the market growth.
- Restrictions for biopharmaceutical businesses to produce these treatments
- Improper reimbursement assessment in medical products for advanced therapy
Advanced Therapy Medicinal Products Market Size and Forecast:
|
Base Year |
2025 |
|
Forecast Period |
2026-2035 |
|
CAGR |
14.5% |
|
Base Year Market Size (2025) |
USD 45.2 billion |
|
Forecast Year Market Size (2035) |
USD 175.06 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of advanced therapy medicinal products is assessed at USD 51.1 billion.
The global advanced therapy medicinal products market size was valued at over USD 45.2 billion in 2025 and is expected to expand at a CAGR of over 14.5%, surpassing USD 175.06 billion revenue by 2035.
North America advanced therapy medicinal products market is predicted to capture 44% share by 2035, driven by higher cases of cancer and neurological disorders and private investment.
Key players in the market include Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene, Inc.
